Sign in
Not yet recruitingPhase 1

Testing a stem cell vesicle treatment for liver cirrhosis

Tests the safety of umbilical cord stem cell vesicles in adults with liver cirrhosis.

Key facts

Who runs it
Vinmec Research Institute of Stem Cell and Gene Technology
Where
Vietnam1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment
Status
Not yet recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
15 Mar 2026
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Umbilical cord mesenchymal stem cell-derived extracellular vesicles
Record updated
16 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis caused by alcohol or by chronic hepatitis B or C. It tests the safety of VinEV-3, tiny particles taken from umbilical cord stem cells and given into a vein.

Age
18 to 75 years
Sex
All sexes
Disease stage
Liver cirrhosis with a Child-Pugh score of 7-12 (a score of how badly the liver works). The cause must be alcohol-related liver disease or chronic hepatitis B or C.
Earlier treatment
People with alcohol-related cirrhosis must have stopped drinking alcohol for at least 3 months. People with hepatitis B or C must have the virus under control by standard clinical criteria.

Main reasons for not taking part

  • Serious kidney problems or blood clotting problems
  • Liver cancer now or suspected, or any past cancer
  • Blood clot in the portal vein (main vein to the liver), or fluid in the belly that does not respond to treatment
  • Pregnancy, breastfeeding, or not using enough birth control
  • Also having HIV, tuberculosis, or another cause of long-term liver disease, or cirrhosis of unknown cause

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Liver cirrhosis due to alcohol-related liver disease or chronic hepatitis B or C
  • Child-Pugh score 7-12
  • Alcohol-related cirrhosis: abstinent from alcohol ≥ 3 months
  • HBV/HCV-related cirrhosis: viral disease controlled according to standard clinical criteria
  • Written informed consent provided

Who cannot take part

  • Use of known hepatotoxic medications within a clinically relevant period
  • Current or suspected hepatocellular carcinoma or history of malignancy
  • Portal vein thrombosis
  • Severe renal, respiratory, cardiovascular, infectious, autoimmune, metabolic, or neurological disorders that may interfere with study participation
  • Coinfection with HIV, tuberculosis, or other causes of chronic liver disease
  • Significant renal dysfunction or coagulation abnormalities
  • Liver cirrhosis of unknown etiology
  • Pregnancy, breastfeeding, or inadequate contraception
  • Refractory ascites at screening

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study Phase 1 clinical trial aimed to evaluate the safety and preliminary efficacy of intravenously administered extracellular vesicles derived from umbilical cord mesenchymal stem cells (UC-MSC-EVs; VinEV-3) in patients with liver cirrhosis. The trial uses a rolling six dose-escalation design, enrolling up to 12 adult patients (18-75 years) with Child-Pugh scores of 7-12.

Read full original descriptionShow less

The results of this study are expected to provide initial clinical evidence supporting the safety and potential therapeutic role of UC-MSC-EVs as a novel cell-free treatment approach for liver cirrhosis.

The group in the trial

  • Treatment RegimenTreatment being tested

    Participants in this experimental arm will receive intravenous VinEV-3. Premedication with Dimedrol will be administered prior to infusion. VinEV-3 will be diluted in 0.9% sodium chloride to a total volume of 100 mL and infused over approximately 60 minutes. A dose-escalation design will be applied with safety-based dose adjustment. Participants will receive three infusions administered at 30 ± 5 day intervals, while continuing standard-of-care treatment. Patients will be followed for safety and clinical outcomes at 3, 6, and 9 months after the first infusion

    Treatment: Umbilical cord mesenchymal stem cell-derived extracellular vesicles

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1 Clinical Trial: Evaluation of the Safety and Preliminary Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell Extracellular Vesicle Therapy in the Treatment of Liver Cirrhosis
Plain-language title
Testing a stem cell vesicle treatment for liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07472270, who can take part
Record updated
16 March 2026